| Recruiting | Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC NCT07465276 | Dana-Farber Cancer Institute | Phase 2 |
| Not Yet Recruiting | De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma NCT07320690 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 3 |
| Not Yet Recruiting | Safety and Efficacy Trial of TV5M01 for Radiation-Induced Mucositis in Head and Neck Cancer Patients. NCT06875791 | Fundacion Clinica Valle del Lili | Phase 1 / Phase 2 |
| Not Yet Recruiting | Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head an NCT05835804 | Centre Hospitalier Universitaire, Amiens | Phase 2 |
| Not Yet Recruiting | Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Cancer NCT06929468 | Simon Jäger | — |
| Recruiting | Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer NCT06736379 | VLP Therapeutics | Phase 1 |
| Terminated | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With NCT06546553 | Pfizer | Phase 1 |
| Recruiting | Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 NCT06223568 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors NCT06285097 | Pfizer | Phase 1 |
| Terminated | Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Can NCT05930938 | Groupe Oncologie Radiotherapie Tete et Cou | Phase 3 |
| Active Not Recruiting | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors NCT05983133 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas NCT06236464 | National Cancer Institute, Naples | — |
| Recruiting | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies NCT05783622 | Janux Therapeutics | Phase 1 |
| Completed | A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Sq NCT05459129 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Unknown | A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN NCT05751512 | Shanghai Miracogen Inc. | Phase 3 |
| Recruiting | A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors NCT05208762 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer NCT04191460 | Erasmus Medical Center | Phase 2 |
| Recruiting | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer NCT05329532 | Scancell Ltd | Phase 1 / Phase 2 |
| Completed | Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region NCT05482880 | Maastricht University Medical Center | — |
| Completed | A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck NCT04830592 | Akamis Bio | Phase 1 |
| Active Not Recruiting | Needs and Preferences of Patients With Head-neck Cutaneous SCC NCT06046625 | Maastricht University Medical Center | — |
| Recruiting | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation NCT05059444 | Guardant Health, Inc. | — |
| Completed | Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. NCT04881045 | Pfizer | Phase 1 |
| Recruiting | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 NCT04787042 | Simcha IL-18, Inc. | Phase 1 / Phase 2 |
| Unknown | Study of HLA-DR in Cell Cultures Isolated From Primary Squamous Cell Carcinoma NCT06041464 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Active Not Recruiting | Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer NCT05931445 | Comprehensive Support Project for Oncology Research | N/A |
| Completed | Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors NCT04609566 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Terminated | Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma Located in the Head and NCT03513042 | Leiden University Medical Center | — |
| Completed | Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data. NCT04672772 | Grupo Español de Tratamiento de Tumores de Cabeza y Cuello | — |
| Terminated | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors NCT04628780 | Pfizer | Phase 1 |
| Terminated | Hemopurifier Plus Pembrolizumab in Head and Neck Cancer NCT04453046 | Aethlon Medical Inc. | N/A |
| Active Not Recruiting | Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurren NCT04590963 | AstraZeneca | Phase 3 |
| Terminated | Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC NCT04659369 | Taizhou Mabtech Pharmaceutical Co.,Ltd | Phase 1 |
| Completed | A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reporte NCT05068609 | Bristol-Myers Squibb | — |
| Terminated | A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation NCT04459715 | EMD Serono Research & Development Institute, Inc. | Phase 3 |
| Completed | CIML NK Cell in Head & Neck Cancer NCT04290546 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunoth NCT04326257 | Dan Zandberg | Phase 2 |
| Completed | Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (Vol NCT03946358 | Centre Hospitalier Universitaire de Besancon | Phase 2 |
| Terminated | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. NCT04152018 | Pfizer | Phase 1 |
| Terminated | Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN NCT04034225 | Sensei Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | De-Escalation Therapy for Human Papillomavirus Negative Disease NCT03944915 | University of Chicago | Phase 2 |
| Completed | IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma NCT03381183 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Unknown | Hyperbaric Radiation Sensitization of Head and Neck Cancers NCT03843671 | National Baromedical Services | Phase 2 |
| Unknown | Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN） NCT03855384 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 |
| Completed | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tum NCT03849469 | Xencor, Inc. | Phase 1 |
| Completed | FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel NCT03723967 | Centre Leon Berard | Phase 2 |
| Recruiting | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors NCT03645928 | Iovance Biotherapeutics, Inc. | Phase 2 |
| Completed | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) NCT03752398 | Xencor, Inc. | Phase 1 |
| Completed | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas NCT03894618 | Shattuck Labs, Inc. | Phase 1 |
| Completed | Definitive Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHN NCT03880396 | Assiut University | — |
| Unknown | Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Ca NCT03830385 | Sun Yat-sen University | Phase 2 |
| Completed | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors NCT03758781 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Terminated | Memory Phenotype and PD-1 Inhibition Response in Oral Cancer NCT03862066 | Medical University of South Carolina | — |
| Completed | Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell NCT03733210 | Andrei Iagaru | Phase 1 |
| Completed | A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma NCT05123950 | Bristol-Myers Squibb | — |
| Completed | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors NCT03689192 | Herlev Hospital | Phase 1 |
| Completed | Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma NCT03635164 | University of Colorado, Denver | Phase 1 |
| Active Not Recruiting | Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy NCT03712566 | University Health Network, Toronto | — |
| Recruiting | VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer NCT03690986 | Emory University | Phase 1 |
| Active Not Recruiting | Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC NCT03646461 | University of California, San Diego | Phase 2 |
| Completed | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies NCT03652077 | Incyte Corporation | Phase 1 |
| Completed | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine NCT03633110 | Genocea Biosciences, Inc. | Phase 1 / Phase 2 |
| Unknown | Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of the Head and Neck NCT03139058 | Centre Hospitalier Universitaire, Amiens | N/A |
| Completed | Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnega NCT03624231 | Ulrich Keilholz | Phase 2 |
| Completed | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Ma NCT03629756 | Arcus Biosciences, Inc. | Phase 1 |
| Completed | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors NCT03517488 | Xencor, Inc. | Phase 1 |
| Completed | Margin-Based Vs. Robust Photon Radiotherapy Planning in IMRT of HN-SQCC NCT03552965 | University of Arkansas | N/A |
| Terminated | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tum NCT03525392 | Ipsen | Phase 1 |
| Completed | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers NCT03454451 | Corvus Pharmaceuticals, Inc. | Phase 1 |
| Terminated | Impact of Ribociclib on Head and Neck Squamous Cell Cancer NCT03179956 | Fox Chase Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCH NCT03341936 | Dana-Farber Cancer Institute | Phase 2 |
| Withdrawn | Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Hea NCT03325465 | University of Chicago | Phase 2 |
| Withdrawn | Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients Wit NCT02686008 | Yale University | Phase 1 |
| Completed | Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible NCT03349710 | Bristol-Myers Squibb | Phase 3 |
| Terminated | Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Exper NCT03246685 | HiberCell, Inc. | Phase 2 |
| Completed | Priming Immunotherapy in Advanced Disease With Radiation NCT03313804 | John L. Villano, MD, PhD | Phase 2 |
| Completed | Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unr NCT03194373 | University of Michigan Rogel Cancer Center | Phase 2 |
| Unknown | Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma NCT03938012 | National University Hospital, Singapore | — |
| Completed | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. NCT03245736 | Seagen Inc. | Phase 2 |
| Terminated | PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck NCT02819752 | Royal Marsden NHS Foundation Trust | Phase 1 |
| Completed | The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and NCT03057613 | Case Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at NCT02841748 | University of Chicago | Phase 2 |
| Unknown | Immunotherapy Study of Evofosfamide in Combination With Ipilimumab NCT03098160 | Threshold Pharmaceuticals | Phase 1 |
| Completed | Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (S NCT03129061 | CellSight Technologies, Inc. | Phase 1 |
| Completed | Saliva-based Detection of CD44 NCT03148665 | Joseph Califano | — |
| Completed | Functional ImaGing of Heterogeneity in Head and Neck Tumors - Validation From Surgical Specimens NCT03160495 | Rigshospitalet, Denmark | — |
| Unknown | A Study Evaluating MM-310 in Patients With Solid Tumors NCT03076372 | Merrimack Pharmaceuticals | Phase 1 |
| Completed | Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinom NCT03083873 | Iovance Biotherapeutics, Inc. | Phase 2 |
| Unknown | The Diagnosis of NPC Using the Probe-based Confocal Laser Endomicroscopy NCT03202173 | Eye & ENT Hospital of Fudan University | N/A |
| Terminated | Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for NCT02952586 | Pfizer | Phase 3 |
| Active Not Recruiting | Ipilimumab for Head and Neck Cancer Patients NCT02812524 | Providence Health & Services | Phase 1 |
| Completed | Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients NCT02882308 | Hellenic Cooperative Oncology Group | Phase 2 |
| Completed | Expansion Trial for Axitinib In Head And Neck Cancer NCT02762513 | University of Michigan Rogel Cancer Center | Phase 2 |
| Unknown | A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Nec NCT02054442 | Radboud University Medical Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck NCT02769520 | Assuntina G. Sacco, MD | Phase 2 |
| Unknown | CTC Detection Rate in SCCHN With a in Vivo Device NCT03071900 | Nanjing Tongren Hospital | N/A |
| Completed | Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC NCT02707588 | Groupe Oncologie Radiotherapie Tete et Cou | Phase 2 |
| Completed | GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Pa NCT02575404 | Providence Health & Services | Phase 1 |
| Completed | Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcino NCT02573493 | Washington University School of Medicine | Phase 2 |
| Completed | Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors NCT02636036 | Akamis Bio | Phase 1 |
| Completed | Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and N NCT01998542 | Mirror Biologics, Inc. | Phase 2 |
| Completed | Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion NCT03330249 | Groupe Oncologie Radiotherapie Tete et Cou | Phase 2 |
| Completed | Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/M NCT02551159 | AstraZeneca | Phase 3 |
| Completed | A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients NCT02473731 | Celldex Therapeutics | Phase 1 |
| Completed | ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors NCT02565758 | AbbVie | Phase 1 |
| Completed | SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head a NCT02543476 | AstraZeneca | — |
| Terminated | Safety Study of MGD009 in B7-H3-expressing Tumors NCT02628535 | MacroGenics | Phase 1 |
| Recruiting | Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer NCT02572778 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | — |
| Completed | Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) NCT02277197 | James J Lee | Phase 1 |
| Terminated | Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib NCT02538627 | Merrimack Pharmaceuticals | Phase 1 |
| Terminated | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors NCT02452424 | Daiichi Sankyo | Phase 1 / Phase 2 |
| Completed | Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell NCT02454179 | Acerta Pharma BV | Phase 2 |
| Terminated | Safety Study of AMG 228 to Treat Solid Tumors NCT02437916 | Amgen | Phase 1 |
| Completed | Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell NCT02369458 | Washington University School of Medicine | Phase 2 |
| Terminated | Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck NCT02429089 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Phase 1 |
| Completed | Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma NCT02296684 | Washington University School of Medicine | Phase 2 |
| Terminated | Safety Study of SEA-CD40 in Cancer Patients NCT02376699 | Seagen Inc. | Phase 1 |
| Unknown | Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and NCT02624128 | National Cancer Institute, Naples | Phase 2 |
| Completed | Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer NCT02350712 | Daiichi Sankyo | Phase 1 |
| Completed | Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy NCT02972216 | Yung Shin Pharm. Ind. Co., Ltd. | — |
| Terminated | A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab NCT02124850 | Celgene | Phase 1 |
| Completed | A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab i NCT02262741 | MedImmune LLC | Phase 1 |
| Completed | Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous NCT02158234 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN NCT02124707 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Completed | Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (Che NCT02105636 | Bristol-Myers Squibb | Phase 3 |
| Unknown | Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYP NCT02765503 | International Atomic Energy Agency | N/A |
| Completed | Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer NCT02031250 | University of Michigan Rogel Cancer Center | Phase 2 |
| Withdrawn | Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase NCT01967927 | University of Arkansas | EARLY_Phase 1 |
| Completed | The Role of Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck C NCT02435602 | Maria Sklodowska-Curie National Research Institute of Oncology | N/A |
| Completed | ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer NCT02002182 | Andrew Sikora | Phase 2 |
| Terminated | Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) NCT01984892 | Nina Bhardwaj | Phase 2 |
| Completed | Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial NCT02022098 | Debiopharm International SA | N/A |
| Completed | Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) NCT01716416 | Washington University School of Medicine | Phase 1 |
| Completed | Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer NCT01774760 | Turku University Hospital | Phase 2 |
| Completed | Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer NCT01783587 | Dana-Farber Cancer Institute | Phase 1 |
| Recruiting | Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients NCT02139020 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | — |
| Withdrawn | A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT) NCT01820312 | University of Arkansas | Phase 2 |
| Completed | Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head NCT01737008 | University Health Network, Toronto | Phase 1 |
| Terminated | A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. NCT01732640 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Completed | Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking His NCT01758731 | University of Colorado, Denver | Phase 1 |
| Completed | Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery NCT01612351 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Terminated | Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma NCT00903461 | University of Pittsburgh | Phase 1 |
| Completed | Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head an NCT01528163 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Phase 2 |
| Completed | Performance of PET 18 F-FDG Coupled to CT With Contrast Injection Iodized in the Diagnosis of Early Recurrence NCT02510872 | University Hospital, Caen | N/A |
| Unknown | Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combin NCT01830556 | Karolinska University Hospital | Phase 2 |
| Completed | Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck NCT01458392 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 |
| Terminated | Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma NCT01488318 | Julie E. Bauman, MD, MPH | Phase 2 |
| Terminated | Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study NCT01221753 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcino NCT01386632 | Sanford Health | Phase 2 |
| Completed | Cabazitaxel - PF Induction Chemotherapy NCT01379339 | Krzysztof Misiukiewicz | Phase 1 |
| Completed | ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Sq NCT01218048 | Robert Ferris | Phase 2 |
| Terminated | Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN NCT01305772 | Neal Ready | Phase 2 |
| Completed | Nutrition and Life QUality Patients With Head and Neck Cancers NCT02510859 | University Hospital, Caen | N/A |
| Terminated | Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers NCT01415986 | University of Arkansas | Phase 2 |
| Terminated | EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of NCT01360827 | Merck KGaA, Darmstadt, Germany | Phase 1 |
| Withdrawn | Effectiveness in Head and Neck Cancer Detection Using Positron Emission Tomography (PET) Insert Device NCT01133262 | Washington University School of Medicine | — |
| Terminated | Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the NCT01015664 | University of Tennessee Cancer Institute | Phase 1 / Phase 2 |
| Terminated | Phase II Study of RAD001 Head and Neck Cancer NCT01051791 | Julie E. Bauman, MD, MPH | Phase 2 |
| Completed | A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitan NCT01177956 | Merck KGaA, Darmstadt, Germany | Phase 3 |
| Unknown | Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin NCT00999700 | Gruppo Oncologico del Nord-Ovest | Phase 3 |
| Completed | Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell NCT00971932 | Merck KGaA, Darmstadt, Germany | Phase 2 |
| Terminated | Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Tr NCT00377247 | University of Pittsburgh | Phase 1 |
| Completed | Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subje NCT01012258 | Merck KGaA, Darmstadt, Germany | Phase 3 |
| Terminated | Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer NCT00901537 | Loma Linda University | Phase 1 |
| Completed | Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Ca NCT00736944 | Washington University School of Medicine | Phase 2 |
| Unknown | Hypoxia-based Dose Escalation With Radiochemotherapy in Head and Neck Cancer NCT02352792 | University Hospital Tuebingen | N/A |
| Completed | Stereotactic Body Radiotherapy for Head and Neck Tumors NCT01344356 | Mercy Research | Phase 4 |
| Completed | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors NCT00625456 | Jennerex Biotherapeutics | Phase 1 |
| Completed | Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous NCT01104922 | David A. Clump, MD, PhD | Phase 2 |
| Terminated | Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head an NCT00570674 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Completed | Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck NCT00513383 | Massachusetts General Hospital | Phase 1 |
| Completed | Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and N NCT00442455 | Grupo de Investigación Clínica en Oncología Radioterapia | Phase 3 |
| Terminated | Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer NCT00272181 | Sesen Bio, Inc. | Phase 2 |
| Completed | 0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck NCT00257738 | University of Maryland, Baltimore | Phase 1 |
| Unknown | Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head NCT00652613 | Tata Memorial Hospital | Phase 2 |
| Completed | A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck C NCT00210470 | Brooklyn ImmunoTherapeutics, LLC | Phase 2 |
| Completed | Study of Unilateral Neck Irradiation in Patients With SCC of the Head and Neck NCT00206752 | Beth Israel Medical Center | N/A |
| Completed | Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX) NCT00206219 | AstraZeneca | Phase 3 |